Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2024
  • October
  • 3
  • US Medicare issues updated rules for second round of drug negotiations
  • Top News

US Medicare issues updated rules for second round of drug negotiations

Market Spectator October 3, 2024
2024-10-02T214347Z_1_LYNXMPEK910TS_RTROPTP_4_HEALTH-USA-DRUGPRICING

By Ahmed Aboulenein

WASHINGTON (Reuters) – The U.S. government will provide more time for negotiations and more chances for drugmakers to submit counter offers during the second round of talks over price cuts for its Medicare program, it said on Wednesday.

WHY IT’S IMPORTANT

The Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, the government health insurance program for millions of Americans age 65 and older and the disabled, by Feb. 1 will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.

The guidance is being closely watched by pharmaceutical manufacturers who make the 15 drugs likely to get picked for negotiations.

CMS said changes to the process, which came after feedback from patients and drugmakers, include meeting with companies earlier in the process and allowing more opportunities for counter offers.

The agency will now meet with drugmakers before making its initial offer, and will hold one of the three allotted negotiation meetings before the deadline for the first counter offer. If a company chooses to counter the government’s offer, it will have two further meetings to negotiate.

KEY QUOTES

“What we plan to do is have meetings with manufacturers before CMS actually sends an initial offer. But then once we have done an initial offer, we will have a first optional negotiation meeting with the manufacturer earlier than we did this past year,” a CMS official told reporters on a press call.

“That will provide us with an opportunity to have a dialogue about the initial offer that CMS has sent, and potentially some early thinking from the manufacturer themselves around how they might do a counteroffer.”

CONTEXT

CMS announced prices for ten drugs in August in its first round of cuts following a year of talks. The prices are set to take effect in January 2026 and will save older Americans $1.5 billion in out of pocket costs, according to the agency.

Next year’s talks will take place in a shorter timeframe, with a final decision on prices due by Nov. 30, 2025.

(Reporting by Ahmed Aboulenein; Editing by Sonali Paul)

About the Author

Market Spectator

Administrator

View All Posts

Post navigation

Previous: Exclusive-Musk funded right-wing political non-profit years before he endorsed Trump, sources say
Next: Oil jumps over $3 a barrel as Middle East conflict stokes supply worry

Related Stories

2024-11-26T190310Z_1_LYNXNPEKAP0TV_RTROPTP_4_USA-TRUMP-NORTHKOREA
  • Top News

Exclusive-Trump team weighs direct talks with North Korea’s Kim in new diplomatic push, sources say

Market Spectator November 26, 2024
2024-11-18T220658Z_1_LYNXMPEKAH0T9_RTROPTP_4_UKRAINE-CRISIS-ATTACK-KYIV-1
  • Top News

Ukraine, marking 1,000 days of Russian invasion, eyes end to war next year

Market Spectator November 18, 2024
  • Top News

Biden sees opportunity to potentially end Israel-Iran fighting ‘for a while’

Market Spectator October 18, 2024

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Categories

  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Uncategorized

Recent Posts

  • European drinks group skid after US surgeon general calls for cancer warnings
  • AI a productivity boost to banks but making money from it is a challenge
  • Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending
  • Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit
  • Stunning rally in Big Tech drives Nasdaq to 20,000

You may have missed

2025-01-03T141432Z_1_LYNXMPEL020G8_RTROPTP_4_PERNOD-RICARD-INDIA-RAJASTHAN
  • Business

European drinks group skid after US surgeon general calls for cancer warnings

Market Spectator January 3, 2025
2024-12-11T214504Z_1_LYNXMPEKBA10D_RTROPTP_4_REUTERS-NEXT-GOLDMAN-SACHS-CEO
  • Business

AI a productivity boost to banks but making money from it is a challenge

Market Spectator December 11, 2024
2024-12-11T212535Z_1_LYNXMPEKBA102_RTROPTP_4_ADOBE-RESULTS
  • Business

Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending

Market Spectator December 11, 2024
2024-12-11T213952Z_1_LYNXMPEKBA109_RTROPTP_4_TECH-ANTIRUST-MICROSOFT
  • Business

Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit

Market Spectator December 11, 2024
  • Home
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Contact Us
Copyright 2025 © All rights reserved | Market Spectator | marketspectator.com